CStone announces first patient dosed in Phase I study in China for MEK inhibitor CS3006

PR Newswire
October 30, 2018 — 10:28 CST

UNLOCK DATA
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech

Want to read this important story?

Access thousands of news articles and data posts over the past 9 years!

Already have an account or paid subscription? Log in

Related Topics: army Australia Beijing China chinese healthcare medicine military pharmaceutical PLA Signal Suzhou venture capital

Related News:

The 9th Asian Winter Games takes place

February 8, 2025 — 19:58

Star-Studded Sponsor Line-up Takes Centre Court at the Singapore Tennis Open 2025

January 28, 2025 — 10:49

Altair Engineering Inc. Stockholders Approve Proposed Merger with Siemens

January 23, 2025 — 05:05

Evolving Global Asset Management Industry in Focus at Asset Abu Dhabi

December 11, 2024 — 02:10

Crystal clear: Pingcheng period glassware of Northern Wei Dynasty

November 9, 2024 — 08:00

Harbour BioMed Announces Submission of IND Application for HBM9378/SKB378 in the Treatment of Chronic Obstructive Pulmonary Disease

November 8, 2024 — 17:45

Live from ESMO 2024 | Ascentage Pharma Releases Latest Data Showing Sustained Clinical Efficacy of Olverembatinib in SDH-Deficient GIST during a Mini Oral Presentation

September 14, 2024 — 08:18

Desay Battery Highlights Advanced Energy Solutions at RE+ 2024

September 11, 2024 — 03:00

Transcenta Holding Limited (Stock Code: 6628.HK) Announce 2024 Interim Results

August 29, 2024 — 14:31

Franchising and Licensing Asia (FLAsia) 2024